Ultragenyx Pharmaceutical Inc. (RARE)

Elevation Oncology Revenue by Segment

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
Product	314.47M	285.47M	265.30M	230.30M	198.70M	180.40M	157.60M	147.80M
Product Growth	58.26%	58.24%	68.34%	55.82%	45.67%	51.72%	43.01%	48.24%
Other	276.21M	274.71M	257.40M	250.90M	243.80M	253.80M	252.60M	245.10M
Other Growth	13.29%	8.24%	1.90%	2.37%	2.65%	8.28%	13.27%	4.56%

Revenue by Geography

Period Ending	Mar 31, 2025	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020
North America	340.56M	340.46M	316.40M	307.30M	297.70M	307.10M	299.00M	298.20M
North America Growth	14.40%	10.86%	5.82%	3.05%	4.02%	9.29%	11.94%	11.69%
Latin America	150.40M	130.71M	130.30M	109.50M	89.70M	77.30M	67.40M	64.30M
Latin America Growth	67.67%	69.10%	93.32%	70.30%	55.46%	72.93%	61.24%	82.67%
Europe	87.45M	80.12M	69.60M	60.40M	54.20M	47.60M	42.70M	38.10M
Europe Growth	61.35%	68.33%	63.00%	58.53%	44.15%	30.77%	28.61%	19.06%
Japan	8.69M	-	6.40M	4.10M	-	2.20M	-	-

Source: Business metrics provided by Main Street Data and sourced from official company press releases and documents.